B cell acute lymphoblastic leukemia therapy: an up to date overview

DOI Web Site PubMed
  • HAYAKAWA Fumihiko
    Division of Cellular and Genetic Sciences, Nagoya University Graduate School of Medicine

Bibliographic Information

Other Title
  • B細胞性急性リンパ性白血病
  • B細胞性急性リンパ性白血病 : 最近の知見と今後の治療
  • Bサイボウ セイキュウセイ リンパセイ ハッケツビョウ : サイキン ノ チケン ト コンゴ ノ チリョウ
  • —最近の知見と今後の治療—

Search this article

Description

<p>It is over two decades since the first retrospective analysis indicated the superiority of pediatric-like therapy for adolescent and young adult (AYA) patients in 2000. To date, many prospective studies confirmed the efficacy and safety of pediatric-like therapy for AYA and older adult ALL, while therapy for pediatric ALL also made progress by innovating a new technology such as stratification of therapy by minimal residual disease (MRD). Furthermore, it is expected that further improvements will be achieved by applying newly approved anti-cancer drugs such as inotuzumab ozogamicin and blinatumomab. In this review, I will introduce these front line studies and discuss about the perspective of adult B-ALL treatment.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 62 (8), 1094-1101, 2021

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top